PKN2
Serine/threonine-protein kinase N2
Protein Summary
PKC-related serine/threonine-protein kinase and Rho/Rac effector protein that participates in specific signal transduction responses in the cell. Plays a role in the regulation of cell cycle progression, actin cytoskeleton assembly, cell migration, cell adhesion, tumor cell invasion and transcription activation signaling processes. Phosphorylates CTTN in hyaluronan-induced astrocytes and hence decreases CTTN ability to associate with filamentous actin. Phosphorylates HDAC5, therefore lead to impair HDAC5 import. Direct RhoA target required for the regulation of the maturation of primordial junctions into apical junction formation in bronchial epithelial cells. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Stimulates FYN kinase activity that is required for establishment of skin cell-cell adhesion during keratinocytes differentiation. Regulates epithelial bladder cells speed and direction of movement during cell migr ...more
- ENST00000370513
- ENSP00000359544
- ENSG00000065243
- ENST00000370521
- ENSP00000359552
- PRK2
- PRKCL2
- PAK2
- PRK2
- STK7
- Pak-2
- PRKCL2
- PRO2042
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug perturbation | 1 | ||
interacting protein | 1 | ||
protein domain | 0.99 | ||
molecular function | 0.98 | ||
transcription factor binding site profile | 0.9 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 115.86 (req: < 5)
Gene RIFs: 27 (req: <= 3)
Antibodies: 225 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 115.86 (req: >= 5)
Gene RIFs: 27 (req: > 3)
Antibodies: 225 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 25
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 40
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1